Your browser is no longer supported. Please, upgrade your browser.
Nutriband Inc.
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week-7.19%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float3.38M Perf Month-
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-
Sales1.39M P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.85 - 4.28 Perf YTD6.90%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-55.61% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low123.50% ATR0.70
Employees3 Current Ratio- Sales Q/Q153.10% Oper. Margin- RSI (14)- Volatility44.08% -
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.01 Prev Close1.55
ShortableNo LT Debt/Eq- Earnings- Payout- Avg Volume124.27K Price1.90
Recom- SMA204.67% SMA504.67% SMA2004.67% Volume737 Change22.58%
Oct-22-21 07:30AM  
Oct-13-21 09:32AM  
Oct-12-21 07:30AM  
Oct-06-21 08:30AM  
Oct-05-21 03:35PM  
Oct-04-21 07:30AM  
Oct-01-21 12:00PM  
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.